Seeking Alpha

Intercept Pharmaceuticals (ICPT -0.8%) says it's completed the enrollment for its Phase III...

Intercept Pharmaceuticals (ICPT -0.8%) says it's completed the enrollment for its Phase III clinical trial of obeticholic acid in primary biliary cirrhosis. Results from the 12-month double-blind portion are anticipated to be available in the Q214 and, if successful, will be used to seek regulatory approval of the drug as a second line treatment for the disease.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|